Press Releases September 4, 2026 04:01 PM

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

Kiniksa Pharmaceuticals to Participate in Wells Fargo's Annual Healthcare Conference

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
KNSA

Kiniksa Pharmaceuticals announced its management will present at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026. The presentation will be webcast live and replayed on their website. Kiniksa focuses on developing novel therapies for debilitating diseases, especially in cardiovascular indications.

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
KNSA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Kiniksa management will participate in a high-profile healthcare investor conference, increasing company visibility.
  • The company focuses on biopharmaceutical innovations targeting diseases with unmet medical needs, particularly cardiovascular conditions.
  • The webcast and replay accessibility could enhance investor and stakeholder engagement.

LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.

Every Second Counts! ®

Kiniksa Investor & Media Contact
Jonathan Kirshenbaum
(781) 829-3949
[email protected]


Risks

  • The company's products are in development or commercialization stages, involving inherent risks of clinical and regulatory setbacks impacting the biopharmaceutical sector.
  • Market competitive pressures within cardiovascular therapy development could impact Kiniksa's prospects.
  • Investor expectations from conference participation may not translate into immediate financial gains, possibly affecting short-term investor sentiment.

More from Press Releases

Alpha Compute Corp. Market Update Sep 4, 2026 HII Details Strategy to Increase Shipbuilding Pace for U.S. Navy Sep 4, 2026 Phaos Technology Holdings (Cayman) Limited Announces Results of Extraordinary General Meeting Sep 4, 2026 Crane NXT to Participate in the 2026 Jefferies Global Industrial Conference Sep 4, 2026 Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards Sep 4, 2026